Medtronic enrolls first patient in ENDURANCE study of Altaviva tibial neuromodulation device

Medtronic Plc

Medtronic Plc

MDT

0.00
  • Medtronic enrolled first patient in ENDURANCE post-approval study of Altaviva implantable tibial neuromodulation device for urge urinary incontinence.
  • Clinical results have not been presented; study will track real-world safety and durability outcomes over five years.
  • Trial aims to show sustained symptom improvement to support broader payer coverage and reimbursement decisions for Altaviva.
  • Altaviva received FDA clearance in September 2025, positioning Medtronic to expand presence in neuromodulation-based bladder care.
  • ENDURANCE plans to follow 170 patients across up to 30 US centers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.